Odanacatib

Generic Name
Odanacatib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C25H27F4N3O3S
CAS Number
603139-19-1
Unique Ingredient Identifier
N673F6W2VH
Background

Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis . The drug made it to phase III trials before abandoned due to increased stroke.

Indication

Investigated for use/treatment in osteoporosis .

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)

Phase 3
Terminated
Conditions
Osteoporosis
Interventions
Other: placebo to odanacatib
Drug: odanacatib
First Posted Date
2013-03-04
Last Posted Date
2019-09-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
135
Registration Number
NCT01803607

A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)

Phase 1
Terminated
Conditions
Osteoporosis
Interventions
Drug: Placebo
Drug: Odanacatib
First Posted Date
2012-06-28
Last Posted Date
2018-08-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
19
Registration Number
NCT01630616

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

First Posted Date
2012-03-13
Last Posted Date
2015-08-27
Lead Sponsor
Merck Sharp & Dohme LLC
Registration Number
NCT01552122

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

First Posted Date
2010-05-11
Last Posted Date
2018-08-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
294
Registration Number
NCT01120600

Safety and Tolerability of Odanacatib (0822-059)

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: Odanacatib
First Posted Date
2010-02-12
Last Posted Date
2018-08-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
44
Registration Number
NCT01068262

A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)

First Posted Date
2009-04-21
Last Posted Date
2018-08-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
246
Registration Number
NCT00885170

A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: odanacatib
First Posted Date
2009-03-18
Last Posted Date
2015-08-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
8
Registration Number
NCT00863525

A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: odanacatib
First Posted Date
2009-03-18
Last Posted Date
2015-08-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
24
Registration Number
NCT00863590

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: odanacatib
First Posted Date
2008-10-09
Last Posted Date
2016-02-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
78
Registration Number
NCT00770159

Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)

Phase 1
Completed
Conditions
Osteoporosis
Interventions
Drug: odanacatib
First Posted Date
2008-10-09
Last Posted Date
2015-08-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
62
Registration Number
NCT00769418
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy